Product image of Lamisil (Terbinafine) supplied by GNH India

Lamisil

Active Ingredient:
Terbinafine
Origin:
EU

Lamisil (Terbinafine)

Terbinafine, the active ingredient in Lamisil, is an allylamine antifungal presented as an oral tablet for systemic use. It treats dermatophyte skin infections and fungal nail disease in adult patients.
GNH India supplies Lamisil as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Novartis Hrvatska D.O.O.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Lamisil is used to treat fungal infections caused by dermatophytes and related organisms.

  • Tinea pedis: relieves itching and clears fungal infection of the feet.
  • Tinea corporis: eliminates ring‑shaped skin lesions caused by dermatophytes.
  • Tinea cruris: treats fungal infection of the groin area.
  • Onychomycosis: improves appearance and clears fungal infection of the toenails and fingernails.

How It Works

  • Terbinafine inhibits fungal squalene epoxidase, causing accumulation of squalene and depletion of ergosterol, an essential component of the fungal cell membrane. This disruption impairs membrane synthesis, leading to fungal cell death and resolution of the infection.

Side Effects

Terbinafine may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

  • Gastrointestinal upset: nausea, abdominal discomfort, or diarrhea.
  • Taste disturbance: altered or loss of taste sensation.
  • Headache: mild to moderate intensity.
  • Skin rash: localized erythema or pruritus.
  • Elevated liver enzymes: mild, transient increases in laboratory tests.

Serious or Rare Side Effects

  • Hepatotoxicity: signs of liver injury such as jaundice or severe enzyme elevation.
  • Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.
  • Blood dyscrasias: agranulocytosis, thrombocytopenia, or anemia.
  • Peripheral neuropathy: numbness or tingling in extremities.
  • Acute interstitial nephritis: kidney inflammation presenting with reduced urine output.

Precautions & Warnings

Before initiating therapy, clinicians should evaluate patient-specific risk factors and monitor for adverse events.

  • Liver function assessment: obtain baseline hepatic enzymes and repeat if symptoms develop.
  • Skin monitoring: watch for rash, blistering, or signs of severe cutaneous reactions.
  • Hypersensitivity: avoid use in patients with known terbinafine allergy.
  • Renal impairment: adjust dosing or monitor renal function in patients with reduced clearance.
  • Drug interactions: review concomitant medications for potential hepatic or CYP interactions.
  • Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Avoid Interactions

Terbinafine can affect the metabolism of several co‑administered drugs, requiring careful management.

Major Interactions (Avoid)

  • Itraconazole: combined use may increase risk of hepatotoxicity.
  • Cimetidine: may raise terbinafine plasma concentrations, enhancing toxicity.
  • CYP2D6 substrates (e.g., tricyclic antidepressants, certain antipsychotics): risk of elevated levels and adverse effects.

Moderate Interactions (Monitor Closely)

  • Warfarin: monitor INR for potential anticoagulant effect changes.
  • Oral contraceptives: assess efficacy as terbinafine may reduce hormonal levels.
  • Antiretroviral agents (e.g., protease inhibitors): observe for altered drug exposure.
  • Statins: watch for increased risk of myopathy.
  • Rifampicin: may reduce terbinafine effectiveness by inducing metabolism.

Frequently Asked Questions

Lamisil is prescribed for infections caused by dermatophyte fungi, including athlete's foot (tinea pedis), body ringworm (tinea corporis), groin infection (tinea cruris), and fungal nail disease (onychomycosis). It works systemically to eliminate the fungus from skin and nails.

Terbinafine blocks the fungal enzyme squalene epoxidase, leading to a buildup of squalene and a shortage of ergosterol, a key component of the fungal cell membrane. This disruption compromises membrane integrity, causing fungal cell death and clearing the infection.

The specific dosage and treatment duration for Lamisil are determined by the prescribing clinician based on the infection type, severity, and patient characteristics. Patients should follow the prescriber’s instructions and not alter the dose on their own.

Safety data for terbinafine in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare professional.

To request Lamisil, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with azole antifungals, terbinafine has a different mechanism—squalene epoxidase inhibition—and often achieves higher cure rates for dermatophyte infections, especially onychomycosis, with a shorter treatment course. However, individual response and safety profiles vary, so clinicians choose therapy based on patient needs.

Lamisil tablets should be stored at temperatures below 25 °C, in their original packaging, protected from moisture and direct sunlight. Keeping the product in a dry, cool place helps maintain its stability and potency throughout its shelf life.

Lamisil is taken orally, usually with or without food, as directed by the prescriber. The tablet should be swallowed whole with a glass of water and not chewed or crushed, unless the prescribing information specifically allows an alternative method.

Serious adverse events include liver injury, severe skin reactions such as Stevens‑Johnson syndrome or toxic epidermal necrolysis, and blood disorders like agranulocytosis. Patients should report symptoms such as jaundice, rash, fever, or unexplained bruising to their healthcare provider promptly.

Lamisil is contraindicated in individuals with known hypersensitivity to terbinafine or any component of the formulation. Caution is also advised for patients with pre‑existing liver disease, severe renal impairment, or those taking medications that strongly interact with terbinafine.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Terbinafine

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT